Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its ...

The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...